title: A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
authors.affiliation: Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: Barbara
authors.initials: B
authors.lastname: Kiesewetter
authors.affiliation: Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: Ella
authors.initials: E
authors.lastname: Willenbacher
authors.affiliation: Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Willenbacher
authors.affiliation: IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.|Salzburg Cancer Research Institute, Salzburg, Austria.
authors.forename: Alexander
authors.initials: A
authors.lastname: Egle
authors.affiliation: Clinical Division of Hematology, Department of Medicine, Medical University of Graz, Graz, Austria.
authors.forename: Peter
authors.initials: P
authors.lastname: Neumeister
authors.affiliation: Center for Hematology and Medical Oncology, Department of Internal Medicine III, Allgemeines Krankenhaus Linz, Linz, Austria; and.
authors.forename: Daniela
authors.initials: D
authors.lastname: Voskova
authors.affiliation: Department of Radiology and.
authors.forename: Marius Erik
authors.initials: ME
authors.lastname: Mayerhoefer
authors.affiliation: Department of Clinical Pathology, Medical University Vienna, Vienna, Austria.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Simonitsch-Klupp
authors.affiliation: IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.|Salzburg Cancer Research Institute, Salzburg, Austria.
authors.forename: Thomas
authors.initials: T
authors.lastname: Melchardt
authors.affiliation: IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.|Salzburg Cancer Research Institute, Salzburg, Austria.
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
authors.affiliation: Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: Markus
authors.initials: M
authors.lastname: Raderer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000069283:Rituximab; D013792:Thalidomide; D000077269:Lenalidomide